Sanofi (SNY) Competitors

Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.

Is SNY or NVO more profitable?

Novo Nordisk A/S has a net margin of 34.81% compared to Sanofi's net margin of 12.77%. Novo Nordisk A/S's return on equity of 84.68% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
Novo Nordisk A/S	34.81%	84.68%	26.29%

Which has more risk and volatility, SNY or NVO?

Sanofi has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Which has stronger valuation & earnings, SNY or NVO?

Novo Nordisk A/S has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$45.17B	3.05	$6.02B	$2.80	19.45
Novo Nordisk A/S	$290.40B	1.01	$14.64B	$3.29	19.86

Do analysts recommend SNY or NVO?

Sanofi currently has a consensus target price of $63.33, suggesting a potential upside of 16.32%. Novo Nordisk A/S has a consensus target price of $135.00, suggesting a potential upside of 106.60%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	3 Strong Buy rating(s)	3.14
Novo Nordisk A/S	2 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.38

Do institutionals & insiders believe in SNY or NVO?

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in SNY or NVO?

Novo Nordisk A/S received 382 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 61.18% of users gave Sanofi an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 52 61.18%	Underperform Votes 33 38.82%
Novo Nordisk A/S	Outperform Votes 434 61.74%	Underperform Votes 269 38.26%

Does the media prefer SNY or NVO?

In the previous week, Novo Nordisk A/S had 30 more articles in the media than Sanofi. MarketBeat recorded 58 mentions for Novo Nordisk A/S and 28 mentions for Sanofi. Sanofi's average media sentiment score of 1.06 beat Novo Nordisk A/S's score of 0.62 indicating that Sanofi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	12 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	28 Very Positive mention(s)	8 Positive mention(s)	12 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Positive

Is SNY or NVO a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.5%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 49.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Novo Nordisk A/S beats Sanofi on 13 of the 21 factors compared between the two stocks.